Literature DB >> 1997392

Type III hyperlipoproteinemia in a patient with idiopathic hemochromatosis.

G Feussner1, R Ziegler.   

Abstract

A 60-year-old man is reported with idiopathic hemochromatosis and type III hyperlipoproteinemia. Regular phlebotomy therapy and fenofibrate treatment favorably influenced the disorder of iron metabolism and the lipid disease. Evidence is given that both errors of metabolism are independently inherited diseases, although the symptoms of the first (idiopathic hemochromatosis) may aggravate the expression of the second (type III hyperlipoproteinemia).

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1997392

Source DB:  PubMed          Journal:  Hum Genet        ISSN： 0340-6717            Impact factor:   4.132


  12 in total

1.  Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis.

Authors:  M Simon; M Bourel; R Fauchet; B Genetet
Journal:  Gut       Date:  1976-05       Impact factor: 23.059

2.  Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III.

Authors:  G Utermann; K H Vogelberg; A Steinmetz; W Schoenborn; N Pruin; M Jaeschke; M Hees; H Canzler
Journal:  Clin Genet       Date:  1979-01       Impact factor: 4.438

3.  Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3.

Authors:  G R Warnick; C Mayfield; J J Albers; W R Hazzard
Journal:  Clin Chem       Date:  1979-02       Impact factor: 8.327

4.  Aggravation of broad- disease (type 3 hyperlipoproteinemia) by hypothyroidism.

Authors:  W R Hazzard; E L Bierman
Journal:  Arch Intern Med       Date:  1972-12

5.  Hypertriglyceridaemia secondary to liver disease.

Authors:  P Müller; R Felin; J Lambrecht; B Agostini; H Wieland; W Rost; D Seidel
Journal:  Eur J Clin Invest       Date:  1974-12-05       Impact factor: 4.686

6.  [Apolipoprotein E polymorphism, hyperlipidemia and risk of myocardial infarct].

Authors:  G Assmann; H J Lenzen
Journal:  Internist (Berl)       Date:  1985-11       Impact factor: 0.743

7.  Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification.

Authors:  V I Zannis; J L Breslow
Journal:  Biochemistry       Date:  1981-02-17       Impact factor: 3.162

Review 8.  Apolipoprotein E polymorphism in health and disease.

Authors:  G Utermann
Journal:  Am Heart J       Date:  1987-02       Impact factor: 4.749

Review 9.  Type III hyperlipoproteinemia: recent insights into the genetic defect of familial dysbetalipoproteinemia.

Authors:  R W Mahley; B Angelin
Journal:  Adv Intern Med       Date:  1984

10.  Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows.

Authors:  W J Schneider; P T Kovanen; M S Brown; J L Goldstein; G Utermann; W Weber; R J Havel; L Kotite; J P Kane; T L Innerarity; R W Mahley
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808
View more
  1 in total

1.  The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.

Authors:  G Feussner; M Eichinger; R Ziegler
Journal:  Clin Investig       Date:  1992-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.